UY30214A1 - Modificaciones de ( 5s) -5-(4-(5-cloro-piridin--2-iloxi)-piperidina-1-sulfonilmetil)-5-metil-imidazolidina-2,4-diona, procesos para su preparacion, composiciones que los contengan y aplicaciones. - Google Patents
Modificaciones de ( 5s) -5-(4-(5-cloro-piridin--2-iloxi)-piperidina-1-sulfonilmetil)-5-metil-imidazolidina-2,4-diona, procesos para su preparacion, composiciones que los contengan y aplicaciones.Info
- Publication number
- UY30214A1 UY30214A1 UY30214A UY30214A UY30214A1 UY 30214 A1 UY30214 A1 UY 30214A1 UY 30214 A UY30214 A UY 30214A UY 30214 A UY30214 A UY 30214A UY 30214 A1 UY30214 A1 UY 30214A1
- Authority
- UY
- Uruguay
- Prior art keywords
- modifications
- imidazolidine
- methyl
- processes
- sulfonilmetil
- Prior art date
Links
- 238000012986 modification Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000004048 modification Effects 0.000 abstract 4
- SFJFBTPHDHUUPU-OAHLLOKOSA-N (5s)-5-[[4-(5-chloropyridin-2-yl)oxypiperidin-1-yl]sulfonylmethyl]-5-methylimidazolidine-2,4-dione Chemical compound C1CC(OC=2N=CC(Cl)=CC=2)CCN1S(=O)(=O)C[C@@]1(C)NC(=O)NC1=O SFJFBTPHDHUUPU-OAHLLOKOSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78297906P | 2006-03-16 | 2006-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30214A1 true UY30214A1 (es) | 2007-10-31 |
Family
ID=38509897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30214A UY30214A1 (es) | 2006-03-16 | 2007-03-15 | Modificaciones de ( 5s) -5-(4-(5-cloro-piridin--2-iloxi)-piperidina-1-sulfonilmetil)-5-metil-imidazolidina-2,4-diona, procesos para su preparacion, composiciones que los contengan y aplicaciones. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090221640A1 (enExample) |
| EP (1) | EP2064202A4 (enExample) |
| JP (1) | JP2009531313A (enExample) |
| KR (1) | KR20090008229A (enExample) |
| CN (1) | CN101448819A (enExample) |
| AR (1) | AR059913A1 (enExample) |
| AU (1) | AU2007225477A1 (enExample) |
| BR (1) | BRPI0709579A2 (enExample) |
| CA (1) | CA2644345A1 (enExample) |
| CL (1) | CL2007000680A1 (enExample) |
| IL (1) | IL193670A0 (enExample) |
| MX (1) | MX2008011641A (enExample) |
| NO (1) | NO20084282L (enExample) |
| TW (1) | TW200800954A (enExample) |
| UY (1) | UY30214A1 (enExample) |
| WO (1) | WO2007106022A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| JP5838226B2 (ja) | 2011-01-13 | 2016-01-06 | バイオ−ファーム ソリューションズ カンパニー リミテッド | フェニルカルバメート誘導体の製造方法 |
| EP2797881B1 (en) | 2011-12-27 | 2018-11-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same |
| WO2014178433A1 (ja) | 2013-05-02 | 2014-11-06 | 株式会社エーピーアイ コーポレーション | α－置換システインもしくはその塩又はα－置換システイン合成中間体の製造方法 |
| CN116033902A (zh) | 2020-06-26 | 2023-04-28 | 伯明翰大学 | 治疗脊髓损伤或相关神经组织损伤的方法 |
| CN114133337A (zh) * | 2020-12-14 | 2022-03-04 | 成都泰蓉生物科技有限公司 | 一种2-取代的赖氨酸的制备方法 |
| CN117820178A (zh) * | 2023-12-26 | 2024-04-05 | 山东泰和科技股份有限公司 | 一种d,l-蛋氨酸的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6172762A (ja) * | 1984-09-17 | 1986-04-14 | Kanegafuchi Chem Ind Co Ltd | 光学活性ヒダントイン類の製造法 |
| GB8618559D0 (en) * | 1986-07-30 | 1986-09-10 | Genetics Int Inc | Rhodococcus bacterium |
| US4983771A (en) * | 1989-09-18 | 1991-01-08 | Hexcel Corporation | Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid |
| NL9000386A (nl) * | 1990-02-16 | 1991-09-16 | Stamicarbon | Werkwijze voor de bereiding van optisch aktief aminozuuramide. |
| DK161690D0 (da) * | 1990-07-05 | 1990-07-05 | Novo Nordisk As | Fremgangsmaade til fremstilling af enantiomere forbindelser |
| NL9201230A (nl) * | 1992-07-09 | 1994-02-01 | Dsm Nv | Werkwijze voor de bereiding van optisch aktief methionineamide. |
| ZA96211B (en) * | 1995-01-12 | 1996-07-26 | Teva Pharma | Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| TW514634B (en) * | 1997-10-14 | 2002-12-21 | Lilly Co Eli | Process to make chiral compounds |
| FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
| CN1509275A (zh) * | 2001-03-15 | 2004-06-30 | 金属蛋白酶抑制剂 | |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| CN1665803A (zh) * | 2002-04-30 | 2005-09-07 | 特瓦药厂有限公司 | 新晶形的昂丹司琼及其制备方法、含有该新晶形的药物组合物以及用其治疗恶心的方法 |
| CN1665504A (zh) * | 2002-05-10 | 2005-09-07 | 特瓦制药工业有限公司 | 新晶型的加替沙星 |
| KR20050010826A (ko) * | 2002-06-05 | 2005-01-28 | 가부시키가이샤 가네카 | 광학 활성 α-메틸시스테인 유도체의 제조 방법 |
| US20040266832A1 (en) * | 2003-06-26 | 2004-12-30 | Li Zheng J. | Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine |
-
2007
- 2007-03-08 TW TW096108012A patent/TW200800954A/zh unknown
- 2007-03-15 CA CA002644345A patent/CA2644345A1/en not_active Abandoned
- 2007-03-15 JP JP2009500326A patent/JP2009531313A/ja active Pending
- 2007-03-15 US US12/282,974 patent/US20090221640A1/en not_active Abandoned
- 2007-03-15 UY UY30214A patent/UY30214A1/es unknown
- 2007-03-15 AU AU2007225477A patent/AU2007225477A1/en not_active Abandoned
- 2007-03-15 EP EP07716068A patent/EP2064202A4/en not_active Withdrawn
- 2007-03-15 BR BRPI0709579-1A patent/BRPI0709579A2/pt not_active IP Right Cessation
- 2007-03-15 WO PCT/SE2007/000256 patent/WO2007106022A2/en not_active Ceased
- 2007-03-15 MX MX2008011641A patent/MX2008011641A/es unknown
- 2007-03-15 KR KR1020087025122A patent/KR20090008229A/ko not_active Withdrawn
- 2007-03-15 CN CNA2007800178360A patent/CN101448819A/zh active Pending
- 2007-03-15 CL CL200700680A patent/CL2007000680A1/es unknown
- 2007-03-16 AR ARP070101073A patent/AR059913A1/es unknown
-
2008
- 2008-08-25 IL IL193670A patent/IL193670A0/en unknown
- 2008-10-13 NO NO20084282A patent/NO20084282L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR059913A1 (es) | 2008-05-07 |
| EP2064202A2 (en) | 2009-06-03 |
| NO20084282L (no) | 2008-10-13 |
| TW200800954A (en) | 2008-01-01 |
| EP2064202A4 (en) | 2011-01-12 |
| CA2644345A1 (en) | 2007-09-20 |
| CL2007000680A1 (es) | 2008-02-08 |
| KR20090008229A (ko) | 2009-01-21 |
| WO2007106022A2 (en) | 2007-09-20 |
| JP2009531313A (ja) | 2009-09-03 |
| BRPI0709579A2 (pt) | 2011-07-19 |
| WO2007106022A3 (en) | 2007-11-01 |
| MX2008011641A (es) | 2008-09-22 |
| AU2007225477A1 (en) | 2007-09-20 |
| US20090221640A1 (en) | 2009-09-03 |
| CN101448819A (zh) | 2009-06-03 |
| IL193670A0 (en) | 2009-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30214A1 (es) | Modificaciones de ( 5s) -5-(4-(5-cloro-piridin--2-iloxi)-piperidina-1-sulfonilmetil)-5-metil-imidazolidina-2,4-diona, procesos para su preparacion, composiciones que los contengan y aplicaciones. | |
| CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| BRPI0922364A2 (pt) | Composto, composição farmacêutica e uso de um composto | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
| CL2008002042A1 (es) | Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos. | |
| CL2007003726A1 (es) | Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer. | |
| CL2007002316A1 (es) | Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer. | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| UY33397A (es) | Forma sólida de un naftaleno carboxamida | |
| CL2007003552A1 (es) | Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
| CL2011001215A1 (es) | Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes. | |
| CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2012000752A1 (es) | Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios. | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| CL2008001879A1 (es) | Compuestos derivados de isaxolinas-naftalen-carboamida; y el uso de los compuestos en el control de plagas de invertebrados en animales. | |
| ECSP109852A (es) | Uso de homo y copolímeros para la estabilización de formulaciones de principios activos | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. |